LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Search

Simulations Plus Inc

Затворен

СекторЗдравеопазване

20.42 0.64

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.15

Максимум

20.74

Ключови измерители

By Trading Economics

Приходи

-70M

-67M

Продажби

-2.1M

20M

P/E

Средно за сектора

48.528

80.03

Дивидентна доходност

0.48

Марж на печалбата

-330.585

Служители

243

EBITDA

327K

5.3M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+0.74% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.48%

2.29%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-7M

344M

Предишно отваряне

19.78

Предишно затваряне

20.42

Настроения в новините

By Acuity

56%

44%

310 / 374 Класиране в Healthcare

Simulations Plus Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.12.2025 г., 23:21 ч. UTC

Печалби
Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3.12.2025 г., 23:14 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3.12.2025 г., 22:01 ч. UTC

Значими двигатели на пазара

Costco Wholesale Reports Higher Monthly Sales

3.12.2025 г., 21:38 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3.12.2025 г., 23:59 ч. UTC

Пазарно говорене

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3.12.2025 г., 23:13 ч. UTC

Пазарно говорене

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3.12.2025 г., 23:10 ч. UTC

Печалби

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3.12.2025 г., 23:08 ч. UTC

Пазарно говорене

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3.12.2025 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3.12.2025 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5M

3.12.2025 г., 22:45 ч. UTC

Пазарно говорене

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3.12.2025 г., 22:20 ч. UTC

Печалби

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3.12.2025 г., 22:19 ч. UTC

Печалби

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3.12.2025 г., 22:17 ч. UTC

Печалби

Salesforce Working to Add Voice to Agentforce, CEO Says

3.12.2025 г., 22:16 ч. UTC

Печалби

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3.12.2025 г., 22:15 ч. UTC

Печалби

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3.12.2025 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.12.2025 г., 21:49 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:23 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3.12.2025 г., 21:19 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:06 ч. UTC

Печалби

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3.12.2025 г., 21:03 ч. UTC

Печалби

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Сравнение с други в отрасъла

Ценова промяна

Simulations Plus Inc Прогноза

Ценова цел

By TipRanks

0.74% нагоре

12-месечна прогноза

Среден 20.5 USD  0.74%

Висок 25 USD

Нисък 16 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Simulations Plus Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

3

Купи

2

Задържане

0

Продай

Настроение

By Acuity

310 / 374 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat